Documents

Core profit up 10% with strong pipeline, margin gains, and positive outlook for sustained growth.

Enicepatide achieved 22.7% weight loss and petrelintide showed strong safety in phase II trials.

Giredestrant and divarasib drive innovation in oncology, with strong growth and pivotal trial results.

AXELIOS sequencing and digital pathology drive robust growth and margin expansion ambitions.

Q1 2026 sales up 6% CER, guidance confirmed, pipeline and launches drive strong growth outlook.

Fenebrutinib demonstrated robust efficacy in MS with a manageable safety profile and broad clinical potential.

Gazyva shows robust efficacy in SLE, supporting strong sales growth and pipeline innovation.

Fenebrutinib matched ocrelizumab in PPMS, offering a high-efficacy oral MS treatment option.

Strong 2025 results with 7% sales growth, robust pipeline, and upgraded 2026 outlook.

Giredestrant showed superior efficacy and safety in early ER+, HER2-negative breast cancer.

Sales up 7% YTD, pharma strong at 9%, pipeline advances, guidance raised, China and FX headwinds.